8-K: Heron Therapeutics Soars on Acute Care Growth, Positive Outlook

Heron Therapeutics announced strong Q4 and full-year 2025 financial results, driven by significant revenue growth in its Acute Care franchise and optimistic 2026 guidance.

Summary

• Heron Therapeutics reported total net revenue of $154.9 million for the full year 2025, marking a 7.4% increase from $144.3 million in 2024.
• The Acute Care franchise, featuring ZYNRELEF and APONVIE, achieved 65.1% year-over-year net revenue growth in 2025, reaching $49.6 million.
• APONVIE revenue surged by 156.1% to $11.6 million in 2025, while ZYNRELEF revenue increased by 49.0% to $38.1 million.
• The Oncology franchise generated $105.3 million in 2025 net revenue, experiencing a 7.8% decrease from 2024, primarily due to declines in SUSTOL (-39.9%) and CINVANTI (-3.3%).
• The company issued full-year 2026 guidance projecting net revenue between $173 million and $183 million and Adjusted EBITDA between $10 million and $20 million.
• Cash, cash equivalents, and short-term investments totaled $46.6 million as of December 31, 2025.
• Net loss for 2025 increased to $(20.2) million from $(13.6) million in 2024, however, Adjusted EBITDA improved significantly to $14.7 million from $6.4 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, primarily driven by the exceptional growth and strategic advancements within the Acute Care franchise, coupled with positive Adjusted EBITDA and optimistic 2026 guidance, despite some headwinds in the Oncology segment.

Positives

• The Acute Care franchise delivered robust revenue growth of 65.1% year-over-year for 2025, reaching $49.6 million.
• APONVIE revenue surged by 156.1% to $11.6 million in 2025, demonstrating strong market adoption.
• ZYNRELEF revenue increased by 49.0% to $38.1 million in 2025, indicating continued commercial acceleration.
• The company achieved a significant improvement in Adjusted EBITDA, reaching $14.7 million in 2025 compared to $6.4 million in 2024.
• Positive 2026 financial guidance projects net revenue of $173 million to $183 million and Adjusted EBITDA of $10 million to $20 million.
• ZYNRELEF received a permanent, product-specific J-Code (J0668) from CMS, effective October 1, 2025, streamlining reimbursement and improving billing clarity.
• The transition to the Vial Access Needle for ZYNRELEF is complete, optimizing product preparation, handling, and operating field sterility.
• APONVIE was included in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV), highlighting its clinical impact.
• APONVIE also received a permanent, product-specific J-Code (J8502) from CMS, enhancing reimbursement clarity.
• A fully dedicated sales team for APONVIE, launched in Q3 2025, is gaining significant momentum in expanding formulary access and driving utilization.

Negatives

• The Oncology franchise net revenue decreased by 7.8% year-over-year in 2025 to $105.3 million, despite complex market dynamics.
• SUSTOL revenue declined significantly by 39.9% to $8.5 million in 2025.
• CINVANTI revenue decreased by 3.3% to $96.8 million in 2025.
• Net loss increased to $(20.2) million in 2025 from $(13.6) million in 2024.
• Total net revenue for Q4 2025 slightly decreased by 0.5% compared to Q4 2024.
• Q4 2025 saw a net loss of $(2.954) million, a shift from a net income of $3.663 million in Q4 2024.

Risks

• Actual results may differ materially from forward-looking statements regarding future operations and financial position.
• Potential market opportunities for ZYNRELEF, APONVIE, CINVANTI, and SUSTOL may not be realized as expected.
• Revenue, Adjusted EBITDA, and other financial guidance provided are subject to uncertainties and may not be achieved.
• Interim financial data or prescription data may not necessarily be indicative of quarterly or annual results.
• The ability to establish and maintain successful commercial arrangements, such as the co-promotion agreement with Crosslink Network, LLC, may face challenges.
• The outcome of pending patent litigations, including potential appeals of any verdicts and settlements, could negatively impact the company.
• There is a risk that the company may be required to write-off additional inventory in the future.
• Future equity financings may be needed to fund operations.
• The company may experience an inability or delay in achieving profitability, including as a result of regulatory developments and policy changes.

Future Outlook

Heron Therapeutics anticipates continued share gains and meaningful revenue expansion in 2026 and beyond, driven by a more powerful commercial engine, expanding demand signals, and improved reimbursement clarity for its Acute Care franchise. The company projects full-year 2026 net revenue between $173 million and $183 million and Adjusted EBITDA between $10 million and $20 million. Development of a Prefilled Syringe market presentation for ZYNRELEF is progressing, with FDA approval anticipated in mid-to-late 2027.

Management Comments

• "We are entering 2026 with exceptional momentum. The fourth quarter delivered the strongest results in the history of Herons Acute Care franchise, underscoring the success of the strategic decisions we implemented to unlock the full potential of these assets." Craig Collard, Chief Executive Officer of Heron.
• "The milestones achieved in 2025, particularly for ZYNRELEF including enhanced distributorpartner incentives, the seamless completion of the Vial Access Needle transition, and CMS approval of a productspecific JCode are already accelerating adoption and strengthening our competitive position in a large and underpenetrated market." Craig Collard, Chief Executive Officer of Heron.
• "With a more powerful commercial engine, expanding demand signals, and improved reimbursement clarity, we believe Heron is wellpositioned for continued share gains and meaningful revenue expansion in 2026 and beyond." Craig Collard, Chief Executive Officer of Heron.

Industry Context

StockSavvy.ai notes that Heron Therapeutics' strong performance in its Acute Care franchise, particularly with ZYNRELEF and APONVIE, aligns with broader trends in healthcare emphasizing enhanced postoperative pain management and antiemetic prophylaxis to improve patient outcomes and reduce hospital stays. The successful navigation of reimbursement complexities with product-specific J-Codes for both ZYNRELEF and APONVIE positions Heron favorably in a competitive market, potentially allowing it to capture market share from traditional pain management and antiemetic solutions. The decline in the Oncology franchise, however, reflects ongoing market dynamics and competitive pressures common in the mature segments of the pharmaceutical industry.

Comparison to Industry Standards

• NA

Legal Proceedings

• The company is involved in pending patent litigations, including potential appeals of any verdicts and settlements.

Stakeholder Impact

• Shareholders: Potential for increased share value due to strong Acute Care growth, improved Adjusted EBITDA, and positive future guidance. However, continued net losses and the potential need for future equity financings could lead to dilution.
• Customers (Hospitals/ASCs/Surgeons): Benefit from improved product access, clearer reimbursement, and optimized product handling (Vial Access Needle) for ZYNRELEF and APONVIE, enhancing patient care.
• Employees: The launch of a dedicated sales team for APONVIE indicates growth and potential opportunities within the company.
• Creditors: Improved Adjusted EBITDA and positive revenue guidance may enhance the company's financial stability and ability to meet obligations.

Next Steps

• Heron will host a conference call and live webcast on February 26, 2026, at 8:30 a.m. ET to discuss these financial results.
• Continued development of the proposed Prefilled Syringe market presentation for ZYNRELEF, with anticipated FDA approval in mid-to-late 2027.
• Further efforts to broaden account access and elevate education around ZYNRELEF's clinical profile through aligned distributor partnerships.
• Continued momentum from the dedicated sales team for APONVIE in expanding formulary access and driving utilization.

Key Dates

Recommendation

The filing demonstrates exceptional growth in the high-potential Acute Care franchise, driven by ZYNRELEF and APONVIE, which are gaining significant market traction supported by strategic initiatives like J-Code approvals and optimized product delivery. The substantial improvement in Adjusted EBITDA and robust 2026 guidance indicate a clear path towards profitability and strong operational performance. While the Oncology segment faces declines, the Acute Care segment's momentum and future prospects, including the ZYNRELEF Prefilled Syringe, present a compelling investment opportunity for long-term growth.

Keywords

Heron Therapeutics, HRTX, Financial Results, Earnings, Biotechnology, Acute Care, Oncology, ZYNRELEF, APONVIE, CINVANTI, SUSTOL, Postoperative Pain, Postoperative Nausea and Vomiting, Chemotherapy Induced Nausea and Vomiting, Net Revenue, Adjusted EBITDA, 2025, 2026 Guidance